Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05758389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Jun 7, 2024 to Aug 7, 2025 Completion date: Jun 7, 2025 to Dec 7, 2025 · Start date: Mar 7, 2023 to Apr 1, 2022v3 Show 2 more changesShow less
    • Completion date: Jun 7, 2025 to Dec 7, 2025
    • Start date: Mar 7, 2023 to Apr 1, 2022
  2. Start date: Mar 3, 2022 to Mar 7, 2023 Primary completion date: Mar 1, 2024 to Jun 7, 2024 · Completion date: Mar 1, 2025 to Jun 7, 2025 · Eligibility criteria expanded, about 4 wordsv2 Show 3 more changesShow less
    • Primary completion date: Mar 1, 2024 to Jun 7, 2024
    • Completion date: Mar 1, 2025 to Jun 7, 2025
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are: 1. evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors. 2. the exploration of efficacy-related immune microenvironment genes Participants will receive tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy.
Trial Details
NCT Number NCT05758389
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Head and Neck Tumors
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov